利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

120 条记录 (耗时 0.111 秒)

    DETECTING AND TREATING ELECTROMECHANICAL DISSOCIATION OF THE HEART
    61.
    发明申请
    DETECTING AND TREATING ELECTROMECHANICAL DISSOCIATION OF THE HEART 有权
    检测和治疗心脏的机械分离

    公开(公告)号：US20100198284A1

    公开(公告)日：2010-08-05

    申请号：US12697019

    申请日：2010-01-29

    申请人： Xiaohong Zhou ,  Paul G. Krause ,  William T. Donofrio

    发明人： Xiaohong Zhou ,  Paul G. Krause ,  William T. Donofrio

    IPC分类号： A61N1/365 ,  A61N1/39

    CPC分类号： A61N1/3627 ,  A61N1/0551 ,  A61N1/36114 ,  A61N1/36557 ,  A61N1/36564 ,  A61N1/3962

    摘要： In some examples, an electromechanical disassociation state (EMD) of a heart of a patient can be treated by delivering electrical stimulation to a tissue site to at least one of modulate afferent nerve activity or inhibit efferent nerve activity upon determining that the heart is in an electromechanical dissociation state, where the tissue site comprises at least one of a nonmyocardial tissue site or a nonvascular cardiac tissue site. The delivery of electrical stimulation may effectively treat the EMD state of the heart, e.g., by enabling effective mechanical contraction of the heart. In another example, an electromechanical disassociation state of a heart of a patient can be treated by determining autonomic nervous system activity associated with a detected EMD state of the heart of a patient, and delivering electrical stimulation therapy to the patient based on the determined autonomic nervous system activity of the patient associated with the EMD state.

    摘要翻译： 在一些示例中，可以通过将电刺激递送至组织部位至少调整传入神经活动或抑制传出神经活动的至少一种来治疗患者心脏的机电解离状态（EMD），确定心脏处于 机电解离状态，其中组织部位包含非心肌组织部位或非血管心脏组织部位中的至少一个。 电刺激的递送可以有效地治疗心脏的EMD状态，例如通过使心脏有效的机械收缩。 在另一个示例中，可以通过确定与患者的心脏的检测到的EMD状态相关联的自主神经系统活动来治疗患者的心脏的机电解离状态，并且基于确定的自主神经向患者输送电刺激疗法 与EMD状态相关的患者的系统活动。

    THERAPY MODULE CROSSTALK MITIGATION
    64.
    发明申请
    THERAPY MODULE CROSSTALK MITIGATION 有权
    治疗模块CROSSTALK减缓

    公开(公告)号：US20100114189A1

    公开(公告)日：2010-05-06

    申请号：US12363180

    申请日：2009-01-30

    申请人： William T. Donofrio ,  Paul G. Krause ,  Gerald P. Arne ,  John E. Burnes ,  David J. Peichel ,  Xiaohong Zhou

    发明人： William T. Donofrio ,  Paul G. Krause ,  Gerald P. Arne ,  John E. Burnes ,  David J. Peichel ,  Xiaohong Zhou

    IPC分类号： A61N1/36

    CPC分类号： A61N1/37288 ,  A61N1/36114

    摘要： A first implantable medical device (IMD) implanted within a patient may communicate with a second IMD implanted within the patient by encoding information in an electrical stimulation signal. The delivery of the electrical stimulation signal may provide therapeutic benefits to the patient. The second IMD may sense the electrical stimulation signal, which may be presented as an artifact in a sensed cardiac signal, and process the sensed signal to retrieve the encoded information. The second IMD may modify its operation based on the received therapy information. Crosstalk between the first and second IMDs may be reduced using various techniques described herein. For example, the first IMD may generate the electrical stimulation signal to include a spread spectrum energy distribution or a predetermined signal signature. The second IMD may effectively remove a least some of the signal artifact in a sensed cardiac signal based on the predetermined signal signature.

    摘要翻译： 植入在患者体内的第一可植入医疗装置（IMD）可以通过对电刺激信号中的信息进行编码来与植入患者内的第二IMD进行通信。 电刺激信号的传递可以为患者提供治疗益处。 第二IMD可以感测电刺激信号，其可以被呈现为感测到的心脏信号中的伪像，并且处理感测到的信号以检索经编码的信息。 第二IMD可以基于接收到的治疗信息修改其操作。 可以使用本文所述的各种技术来减少第一和第二IMD之间的串扰。 例如，第一IMD可以产生电刺激信号以包括扩频能量分布或预定信号特征。 基于预定的信号签名，第二IMD可以有效地去除感测到的心脏信号中的至少一些信号伪像。

    IMPLANTABLE MEDICAL DEVICE HAVING OPTICAL FIBER FOR SENSING ELECTRICAL ACTIVITY
    65.
    发明申请
    IMPLANTABLE MEDICAL DEVICE HAVING OPTICAL FIBER FOR SENSING ELECTRICAL ACTIVITY 有权
    具有用于传感电活动的光纤的可植入医疗装置

    公开(公告)号：US20080200769A1

    公开(公告)日：2008-08-21

    申请号：US11676128

    申请日：2007-02-16

    申请人： VINOD SHARMA ,  Xiaohong Zhou

    发明人： VINOD SHARMA ,  Xiaohong Zhou

    IPC分类号： A61N5/06

    CPC分类号： A61B5/0071 ,  A61B5/0084 ,  A61B5/0452

    摘要： An implantable medical device for optically sensing action potential signals in excitable body tissue. The device includes an elongated tubular lead body carrying an optical fiber extending from a proximal lead end to a distal lead end to position the optical fiber at a target site. The lead body additionally carries a conduit for dispensing a voltage-sensitive fluorescent dye into tissue surrounding the target site. The optical fiber transmits excitation light to the fluorescent dye to cause the dye to fluoresce with varying intensity as the transmembrane potentials of local tissue cells vary due to passing depolarization wavefronts. The optical fiber transmits the fluorescence signal to the device to generate an action potential signal or fiducial points of an action potential signal for use in accurately measuring and characterizing electrical activity of excitable tissue.

    摘要翻译： 一种用于在可兴奋的身体组织中光学感测动作电位信号的可植入医疗装置。 该装置包括细长的管状引线体，其承载从近侧引线端延伸到远端引线端的光纤，以将光纤定位在目标部位。 引线体还带有用于将电压敏感的荧光染料分配到靶区域周围的组织中的导管。 光纤将激发光透射到荧光染料，以使得染料以不同的强度发荧光，因为局部组织细胞的跨膜电位由于通过去极化波前而变化。 光纤将荧光信号传输到设备以产生动作电位信号或动作电位信号的基准点，用于精确测量和表征可兴奋组织的电活动。

    QUINAZOLE DERIVATIVES
    66.
    发明申请
    QUINAZOLE DERIVATIVES 审中-公开
    喹唑啉衍生物

    公开(公告)号：US20080177068A1

    公开(公告)日：2008-07-24

    申请号：US11939244

    申请日：2007-11-13

    申请人： Wenlin Huang ,  Xiaohong Zhou

    发明人： Wenlin Huang ,  Xiaohong Zhou

    IPC分类号： C07D239/94

    CPC分类号： C07D239/94

    摘要： The present invention relates to quinazoline derivatives represented by general formula (I): wherein X, Y, Z, R1, R2, R3, and R4 are as defined herein. The invention also relates to a method of preparing these compounds, and use of these compounds for inhibiting tumor growth.

    摘要翻译： 本发明涉及由通式（I）表示的喹唑啉衍生物：其中X，Y，Z，R 1，R 2，R 3， >和R 4'如本文所定义。 本发明还涉及制备这些化合物的方法，以及这些化合物用于抑制肿瘤生长的用途。

    Methods and apparatus for the regulation of hormone release
    67.
    发明授权
    Methods and apparatus for the regulation of hormone release 有权
    用于调节激素释放的方法和装置

    公开(公告)号：US07221979B2

    公开(公告)日：2007-05-22

    申请号：US10426610

    申请日：2003-04-30

    申请人： Xiaohong Zhou ,  Thomas J. Mullen ,  Gary W. King ,  Michael R. S. Hill

    发明人： Xiaohong Zhou ,  Thomas J. Mullen ,  Gary W. King ,  Michael R. S. Hill

    IPC分类号： A61N1/00

    CPC分类号： A61N1/36071 ,  A61N1/205 ,  A61N1/36021

    摘要： A method and apparatus for delivering corrective therapy through hormone regulation is provided. Inhibition of sympathetic fibers by spinal cord stimulation is used to regulate the levels of hormones such as catecholamines, renin, and calcitonin gene-related peptide. The invention utilizes a closed or open loop feedback system in which physiological parameters such as the concentrations of hormones and sympathetic indicators such as heart rate and urine production are monitored and used to determine the appropriate level of neurostimulation. The site of electrical stimulation includes, but is not limited to, the spinal cord at levels T7–L2 and the associated neural fibers within a region of the T7–L2 dermatomes

    摘要翻译： 提供了一种通过激素调节进行矫正治疗的方法和装置。 通过脊髓刺激抑制交感神经纤维用于调节激素水平，如儿茶酚胺，肾素和降钙素基因相关肽。 本发明利用封闭或开环反馈系统，其中监测诸如心率和尿液产生之间的激素和交感神经指标的生理参数，并用于确定适当的神经刺激水平。 电刺激部位包括（但不限于）T7-L2级别的脊髓和T7-L2皮肌的区域内的相关神经纤维

    Field stimulation about a discontinuity of the myocardium to capture the heart at reduced pacing thresholds
    68.
    发明授权
    Field stimulation about a discontinuity of the myocardium to capture the heart at reduced pacing thresholds 失效

    公开(公告)号：US07142928B2

    公开(公告)日：2006-11-28

    申请号：US10308302

    申请日：2002-12-03

    申请人： Vinod Sharma ,  Xiaohong Zhou

    发明人： Vinod Sharma ,  Xiaohong Zhou

    IPC分类号： A61N1/05 ,  A61N1/04

    CPC分类号： A61N1/0587 ,  A61N1/0573

    摘要： Improved pacing thresholds for capturing the heart are achieved by forming a discontinuity in the cardiac tissue of the heart chamber, disposing a pacing electrode at a distance exceeding a space constant of the cardiac tissue from the discontinuity in the cardiac tissue, and applying a stimulus of a first polarity at an energy insufficient to cause the directly stimulated tissue adjacent to the pacing electrode to propagate a depolarization wave through the cardiac tissue mass of the heart chamber but sufficient to induce a transmembrane potential change at the tissue adjacent to the discontinuity that results in a propagated wave front. Thus, pacing energy is advantageously reduced.

    Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure
    70.
    发明申请
    Delivery of a sympatholytic cardiovascular agent to the central nervous system to counter heart failure and pathologies associated with heart failure 有权
    向中枢神经系统递送交感神经心血管药物以对抗心力衰竭和与心力衰竭相关的病理

    公开(公告)号：US20050177135A1

    公开(公告)日：2005-08-11

    申请号：US10773965

    申请日：2004-02-06

    申请人： Keith Hildebrand ,  Michael Ujhelyi ,  Xiaohong Zhou ,  Daniel Sigg ,  Linda Page

    发明人： Keith Hildebrand ,  Michael Ujhelyi ,  Xiaohong Zhou ,  Daniel Sigg ,  Linda Page

    IPC分类号： A61B5/02 ,  A61M5/142 ,  A61M5/168 ,  A61M5/172 ,  A61N1/39 ,  A61K9/22

    CPC分类号： A61M5/142 ,  A61M5/14276 ,  A61M5/1723 ,  A61M2005/14208 ,  A61M2205/3523 ,  A61M2230/00 ,  A61M2230/04 ,  A61M2230/63 ,  A61N1/3962

    摘要： A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms and otherwise treat heart failure (HF) and pathologies associated with HF. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with HF (or pathologies associated with HF) and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist, e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine.

    摘要翻译： 由药物输送泵递送至中枢神经系统部位的交感神经心血管药物以缓解症状，另外治疗与HF有关的心力衰竭（HF）和病理学。 药物输送泵可以是外部或植入式输液泵（IIP），其与延伸到现场的药物输注导管结合。 患者活化剂可以命令递送剂量和/或与传感器耦合的可植入心脏监测器（IHM）可以检测与HF相关的生理学参数（或与HF相关的病理学）和触发剂量递送。 IIP和IHM可以组合成单个可植入医疗设备（IMD），或者可以构成通过任何已知的通信机制进行通信的单独IMD。 交感神经心血管药剂是由α-肾上腺素能激动剂和α2-肾上腺素能激动剂组成的组之一，例如可乐定，对氨基可乐定，胍苯胺，利脒，替扎尼定，莫西康定，甲基多巴，甲苯噻嗪，胍法辛，美托咪定，美托咪定和 右美托咪定。